Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: BioBait who wrote (3413)	12/8/2021 8:34:06 AM
From: Felix B	Respond to of 3559

That is interesting idea. I wish the website showed total distribution as opposed up until Sept in the table.

To: BioBait who wrote (3413)	12/8/2021 1:04:26 PM
From: CuttingEdge Bio	1 Recommendation Recommended By pheilman_ Respond to of 3559

There are too many Delta cases still in the US to stop using it. And VIR/GSK do not have the manufacturing capacity to supply this market on its own. What they really need to do is a very specific policy (Until REGN has an updated product available). If your PCR had S gene dropout, then you likely have Omicron and you should get Sotrovimab. If your PCR test did NOT have S gene dropout, then you have Delta and should get REGN Cov. This is actually simple. Most efficient and effective use of resources. Using the drug for people it works for and using the other drug for people it doesn't work for. It is not hard at all because every test will theoretically have this information available. Yet at the same time this is impossible. They don't currently provide any information to the customer in almost all cases. You don't even get informed of your CT count. You are told positive or negative. Finished. Certainly if labs are reporting Sgene result to the testers they are not passing this info to the customer. Most people providing tests and test results don't even know what a CT count is. This simple, easy, efficient idea to base treatment on Sgene adds a level of "complexity" (something that isn't really complex at all) to a testing system that drones along and cannot handle even a small change. For that reason it is not viable. But I am fairly certain FDA will obstruct any quick substitution of the product with new antibodies even though at this point it will be completely irrational to do so, and if Omicron can actually kill people, it will get a lot of people killed while we wait for a regulatory process not fit for purpose. I am not optimistic.

To: BioBait who wrote (3413)	12/8/2021 1:08:57 PM
From: CuttingEdge Bio	Respond to of 3559

Sorry I read this wrong initially. You didn't propose to stop distributing Regn cov but were asking why Sotrovimab doses were 0 for the past few weeks. I suspect that perhaps the supply ran out. Their supply deal was small and they have limited manufacturing capacity. I hope I'm wrong but doses may have run out. If someone somewhere up the chain was genius enough to halt Sotrovimab to save it for a potential Omicron outbreak that is coming, I would be very pleasantly surprised.